2. UroToday Home
  3. Trials in Progress

Trials in Progress

PROMISE PCCTC Study: Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Trials in Progress
Videos
Publications
Articles and Abstracts

Germline testing for prostate cancer (PCA) is revolutionizing treatment, management, and risk assessment. Pathogenic mutations in multiple DNA repair genes, and particularly BRCA2 and others, are informing targeted therapy options in the metastatic and advanced disease setting, active surveillance discussions in the early-stage setting, and PCA early detection discussions.1

Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing.

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

  • Condition: Prostate Cancer
  • Study ID: NCT04995198
VIEW TRIAL
Conference Coverage
Conference Highlights Written by Physician Scientists
Presented by Madeleine Karpinski
Madeleine Karpinski discussed the three-tier risk stratification of prostate cancer by PSMA-PET PROMISE (PPP2).
Presented by Wolfgang Peter Fendler, MD
Wolfgang Peter Fendler, MD, presented Poster 5045: Updated prostate cancer risk groups by PSMA-PET PROMISE (PPP2): Results from an international multi-centre registry study.
Presented by Wolfgang P. Fendler, MD
Wolfgang P. Fendler, MD, discussed prostate cancer risk groups by PSMA-PET PROMISE results from an international multi-center registry study.
Presented by Wolfgang P. Fendler, MD
Wolfgang P. Fendler, MD, discussed PSMA-PET and PROMISE re-defining stage and risk in patients with prostate cancer.
Presented by Zeynep Busra Zengin, MD
Novel androgen receptor targeted agents (ARTA) are effective in improving patient outcomes across the spectrum of prostate cancer disease states. Resistance to ARTAs eventually develops in advanced prostate cancer, and a broader understanding of the mechanisms promoting this resistance is required.
Presented by Channing Judith Paller, MD
A substantial minority of patients with prostate cancer have germline mutations in genes involved in DNA damage repair. Based on the prevalence of these alterations in advanced disease and the potential therapeutic benefit of targeting germline DNA damage repair vulnerabilities, treatment guidelines recommend genetic testing in high-risk localized, node positive, and metastatic disease.

Links